FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129409059> ?p ?o ?g. }

• W2129409059 endingPage "1659" @default.
• W2129409059 startingPage "1655" @default.
• W2129409059 abstract "ABSTRACT The delineation of optimal regimens for combinations of agents is a difficult problem, in part because, to address it, one needs to (i) have effect relationships between the pathogen in question and the drugs in the combination, (ii) have knowledge of how the drugs interact (synergy, antagonism, and additivity), and (iii) address the issue of true between-patient variability in pharmacokinetics for the drugs in the population. We have developed an approach which employs a fully parametric assessment of drug interaction using the equation of W. R. Greco, G. Bravo, and J. C. Parsons (Pharmacol. Rev. 47:331–385, 1995) to generate an estimate of effects for the two drugs and have linked this approach to a population simulator, using Monte Carlo methods, which produce concentration-time profiles for the drugs in combination. This software automatically integrates the effect over a steady-state dosing interval and produces an estimate of the mean effect over a steady-state interval for each simulated subject. In this way, doses and schedules can be easily evaluated. This software allows for a rational choice of dose and schedule for evaluation in clinical trials. We evaluated different schedules of administration for the combination of the nucleoside analogue abacavir plus the human immunodeficiency virus type 1 protease inhibitor amprenavir. Amprenavir was simulated as either 800 mg every 8 h (q8h) or 1,200 mg q12h, each along with 300 mg q12h of abacavir. Both regimens produced excellent effects over the simulated population of 500 subjects, with average percentages of maximal effect (as determined from the in vitro assays) of 90.9% ± 11.4% and 80.9% ± 18.6%, respectively. This difference is statistically significant ( P ≪ 0.001). In addition, 68.8 and 46.0% of the population had an average percentage of maximal effect which was greater than or equal to 90% for the two regimens. We can conclude that the combination of abacavir plus amprenavir is a potent combination when it is given on either schedule. However, the more fractionated schedule for the protease inhibitor produced significantly better effects in combination. Clinicians need to explicitly balance the improvement in antiviral effect seen with the more fractionated regimen against the loss of compliance attendant to the use of such a regimen. This approach may be helpful in the preclinical evaluation of multidrug anti-infective regimens." @default.
• W2129409059 created "2016-06-24" @default.
• W2129409059 creator A5013433944 @default.
• W2129409059 creator A5018375392 @default.
• W2129409059 creator A5022472681 @default.
• W2129409059 creator A5023993437 @default.
• W2129409059 creator A5024795578 @default.
• W2129409059 creator A5027239674 @default.
• W2129409059 creator A5036512885 @default.
• W2129409059 creator A5051766126 @default.
• W2129409059 creator A5075562434 @default.
• W2129409059 creator A5091602057 @default.
• W2129409059 date "2000-06-01" @default.
• W2129409059 modified "2023-10-17" @default.
• W2129409059 title "Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir" @default.
• W2129409059 cites W1968157528 @default.
• W2129409059 cites W1987833086 @default.
• W2129409059 cites W1997364324 @default.
• W2129409059 cites W2058299739 @default.
• W2129409059 cites W2110442882 @default.
• W2129409059 cites W2165080361 @default.
• W2129409059 doi "https://doi.org/10.1128/aac.44.6.1655-1659.2000" @default.
• W2129409059 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/89928" @default.
• W2129409059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10817724" @default.
• W2129409059 hasPublicationYear "2000" @default.
• W2129409059 type Work @default.
• W2129409059 sameAs 2129409059 @default.
• W2129409059 citedByCount "51" @default.
• W2129409059 countsByYear W21294090592012 @default.
• W2129409059 countsByYear W21294090592013 @default.
• W2129409059 countsByYear W21294090592014 @default.
• W2129409059 countsByYear W21294090592016 @default.
• W2129409059 countsByYear W21294090592017 @default.
• W2129409059 countsByYear W21294090592018 @default.
• W2129409059 countsByYear W21294090592021 @default.
• W2129409059 crossrefType "journal-article" @default.
• W2129409059 hasAuthorship W2129409059A5013433944 @default.
• W2129409059 hasAuthorship W2129409059A5018375392 @default.
• W2129409059 hasAuthorship W2129409059A5022472681 @default.
• W2129409059 hasAuthorship W2129409059A5023993437 @default.
• W2129409059 hasAuthorship W2129409059A5024795578 @default.
• W2129409059 hasAuthorship W2129409059A5027239674 @default.
• W2129409059 hasAuthorship W2129409059A5036512885 @default.
• W2129409059 hasAuthorship W2129409059A5051766126 @default.
• W2129409059 hasAuthorship W2129409059A5075562434 @default.
• W2129409059 hasAuthorship W2129409059A5091602057 @default.
• W2129409059 hasBestOaLocation W21294090592 @default.
• W2129409059 hasConcept C112705442 @default.
• W2129409059 hasConcept C142462285 @default.
• W2129409059 hasConcept C159047783 @default.
• W2129409059 hasConcept C181199279 @default.
• W2129409059 hasConcept C2776714187 @default.
• W2129409059 hasConcept C2777288759 @default.
• W2129409059 hasConcept C2777363262 @default.
• W2129409059 hasConcept C2777583353 @default.
• W2129409059 hasConcept C2779465607 @default.
• W2129409059 hasConcept C2908647359 @default.
• W2129409059 hasConcept C2993143319 @default.
• W2129409059 hasConcept C3013748606 @default.
• W2129409059 hasConcept C55493867 @default.
• W2129409059 hasConcept C71924100 @default.
• W2129409059 hasConcept C86803240 @default.
• W2129409059 hasConcept C98274493 @default.
• W2129409059 hasConcept C99454951 @default.
• W2129409059 hasConceptScore W2129409059C112705442 @default.
• W2129409059 hasConceptScore W2129409059C142462285 @default.
• W2129409059 hasConceptScore W2129409059C159047783 @default.
• W2129409059 hasConceptScore W2129409059C181199279 @default.
• W2129409059 hasConceptScore W2129409059C2776714187 @default.
• W2129409059 hasConceptScore W2129409059C2777288759 @default.
• W2129409059 hasConceptScore W2129409059C2777363262 @default.
• W2129409059 hasConceptScore W2129409059C2777583353 @default.
• W2129409059 hasConceptScore W2129409059C2779465607 @default.
• W2129409059 hasConceptScore W2129409059C2908647359 @default.
• W2129409059 hasConceptScore W2129409059C2993143319 @default.
• W2129409059 hasConceptScore W2129409059C3013748606 @default.
• W2129409059 hasConceptScore W2129409059C55493867 @default.
• W2129409059 hasConceptScore W2129409059C71924100 @default.
• W2129409059 hasConceptScore W2129409059C86803240 @default.
• W2129409059 hasConceptScore W2129409059C98274493 @default.
• W2129409059 hasConceptScore W2129409059C99454951 @default.
• W2129409059 hasIssue "6" @default.
• W2129409059 hasLocation W21294090591 @default.
• W2129409059 hasLocation W21294090592 @default.
• W2129409059 hasLocation W21294090593 @default.
• W2129409059 hasOpenAccess W2129409059 @default.
• W2129409059 hasPrimaryLocation W21294090591 @default.
• W2129409059 hasRelatedWork W2004159238 @default.
• W2129409059 hasRelatedWork W2107317581 @default.
• W2129409059 hasRelatedWork W2136344807 @default.
• W2129409059 hasRelatedWork W2141289501 @default.
• W2129409059 hasRelatedWork W2162491061 @default.
• W2129409059 hasRelatedWork W2416259257 @default.
• W2129409059 hasRelatedWork W2960553615 @default.
• W2129409059 hasRelatedWork W3043458966 @default.
• W2129409059 hasRelatedWork W4302767925 @default.
• W2129409059 hasRelatedWork W4364376666 @default.
• W2129409059 hasVolume "44" @default.

• next